Table 1. Effects of PK stimulators and... | American Society of Hematology

Table 1.

Effects of PK stimulators and inhibitors on FANCA phosphorylation

Agent	Major target	Assay	Effect
PK stimulator
cAMP (4 μM)	cAMP-dependent PK	In vitro	−
cGMP (4 μM)	cGMP-dependent PK	In vitro	−
Calcium (100 μM)	Calmodulin-dependent PK	In vitro	−
PMA (100 nM)	Protein kinase C	In vivo^†	−
PK inhibitor
cAMP inhibitor protein^* (10 U/assay)	cAMP-dependent PK	In vitro	−
KT5823 (1 μM)	cGMP-dependent PK	In vitro	−
AIP (1 μM)	Calmodulin-dependent PK	In vitro	−
Calfostin (500 nM)	Protein kinase C	In vitro	−
Hypericin (50 nM)	MAPK, casein kinase II	In vitro	−
PD98059 (50 μM)	MAPK kinase	In vivo	−
SB203580 (10 μM)	p38 MAPK	In vivo	−
Rapamycin (20 nM)	FRAP	In vivo	−
Aspirin (5 mM)	IKK-2	In vivo	−
(1 mM)		In vitro	−

Agent	Major target	Assay	Effect
PK stimulator
cAMP (4 μM)	cAMP-dependent PK	In vitro	−
cGMP (4 μM)	cGMP-dependent PK	In vitro	−
Calcium (100 μM)	Calmodulin-dependent PK	In vitro	−
PMA (100 nM)	Protein kinase C	In vivo^†	−
PK inhibitor
cAMP inhibitor protein^* (10 U/assay)	cAMP-dependent PK	In vitro	−
KT5823 (1 μM)	cGMP-dependent PK	In vitro	−
AIP (1 μM)	Calmodulin-dependent PK	In vitro	−
Calfostin (500 nM)	Protein kinase C	In vitro	−
Hypericin (50 nM)	MAPK, casein kinase II	In vitro	−
PD98059 (50 μM)	MAPK kinase	In vivo	−
SB203580 (10 μM)	p38 MAPK	In vivo	−
Rapamycin (20 nM)	FRAP	In vivo	−
Aspirin (5 mM)	IKK-2	In vivo	−
(1 mM)		In vitro	−

PMA indicates phorbol-12-myristate-13-acetate; AIP, autocamitide-2–related inhibitory protein; and MAPK, mitogen-activated PK.

Recombinant PK A heat-stable inhibitor, isoform α.

³²P-labeled cells were treated with PMA for 10 minutes and in vivo phosphorylation of FANCA was estimated.